Breast
Cervical
Colorectal
Esophageal / Gastric
Multiple myeloma
Non-Hodgkin's lymphoma
Non-small-cell lung
Ovarian
Pancreatic
Prostate
Small-cell lung
Soft tissue sarcoma
Testicular
Uterine
In addition, information is included for 18 common patient-specific risk factors that could potentially increase a patient’s chances of developing FN.
The FN Risk Web Portal is for educational background use only. It does not contain an exhaustive or complete list of regimens or other treatment options or risk factors and is not intended as medical advice, a clinical practice guideline, substitution for clinical judgment, or a recommendation on how to assess febrile neutropenia (FN) risk. All chemotherapy regimen and risk factor information should be confirmed independently.
Breast Cancer
Select a Regimen
Select Patient Risk Factors
Risk factors are independent of tumor type and regimen
Breast Cancer
REGIMEN RISK OF FN: -
Regimen References
COVID-19
*Referenced with permission from the National Comprehensive Cancer Network, Inc. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed July 13, 2020. To view the most recent and complete version of the recommendations, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Information provided is on select patient risk factors associated with chemotherapy induced
neutropenia based on national clinical practice guidelines or published literature. It does not contain
an exhaustive or complete list of regimens or other treatment options or risk factors. It is not
intended or to be viewed as medical advice, a clinical practice guideline, or a recommendation on how to
assess febrile neutropenia (FN) risk. It does not substitute clinical judgment. All chemotherapy regimen
and risk factor information should be confirmed independently.
- ICD-10-CM codes are from the ICD-10 Manual on the CMS website. Providers should contact each insurer
to determine the appropriate codes for the services provided. The authors do not guarantee that use of
any code(s) will ensure coverage or payment at any level. The information presented is for informational
purposes only and is not intended to provide reimbursement or legal advice.
- The authors make no claims regarding the accuracy of the information contained herein.
Patient Risk Factors for FN in Addition to Chemotherapy Regimen and Cancer Type
RISK FACTOR references
- None
Risk of chemotherapy was determined high as defined by NCCN Guidelines* and additional
clinical data**
*NCCN defines FN risk of > 20% as high - NCCN Guidelines for Hematopoietic Growth Factors. Version 2.2020.
**Other clinical data considers FN risk of ≥ 17% as high - Vogel CL, et al. J Clin Oncol. 2005: PMID:
15718314
Risk of chemotherapy was determined intermediate as defined by NCCN Guidelines* and additional clinical data**
*NCCN defines FN risk of 10-20% as intermediate - NCCN Guidelines for Hematopoietic Growth Factors. Version 2.2020.
**Other clinical data considers FN risk of 10 to < 17% as intermediate - Vogel CL, et al. J Clin Oncol. 2005: PMID: 15718314
This information provided is on select chemotherapy regimens that are generally viewed based on national clinical practice guidelines or published literature to be associated with an intermediate or high risk of FN as well as information on select patient risk factors associated with chemotherapy induced FN according to national clinical practice guidelines or published literature. It is not intended or to be viewed as medical advice, a clinical practice guideline, or a recommendation on how to assess febrile neutropenia (FN) risk. It does not substitute clinical judgment. All chemotherapy regimen and risk factor information should be confirmed independently. The authors make no claims regarding the accuracy of the information contained in the portal.
